Join Lantern Pharma to learn the broad range of topics surrounding synthetic lethality, including: a brief history of synthetic lethality in oncology, how synthetic lethality is being leveraged to successfully treat cancers with DDR deficiencies, the promising potential of LP-184’s synthetic lethality for DDR deficient tumors, and the potential to combine LP-184 with FDA approved agents to enhance LP-184’s anti-tumor potency.

Learn more and register here.